Rare diseases
Investigational molecules
Locations
275 Shoreline Drive Suite 300, 94065-1490, United States
Clinical research in advanced and recurrent endometrial cancer, with attention to TP53 wild-type disease and maintenance therapy strategies.
Interest centres on disease control in patients with persistent or returning endometrial malignancy.
Kartos Therapeutics Inc. runs clinical trials in conditions such as Myelofibrosis, Primary myelofibrosis, Endometrial cancer, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib
AustriaStudy on the Safety and Effectiveness of Navtemadlin and Ruxolitinib for Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
FranceStudy of Navtemadlin for Patients with Myelofibrosis Resistant to JAK Inhibitors
BulgariaStudy of Navtemadlin as Maintenance Therapy for Patients with Advanced or Recurrent Endometrial Cancer After Chemotherapy
AustriaIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
